Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Cellav Health and Aesthetics Ltd., a subsidiary of Pluri Inc., is a biotechnology company specializing in regenerative aesthetics and longevity solutions. Leveraging Pluri's proprietary 3D cell-expansion platform, Cellav develops advanced cell-based products, including exosome-based technologies and bioactive ingredients derived from plant and human placental sources. The company's flagship products, Regenativo+ and Placento+, are designed for professional topical use to improve skin elasticity, firmness, and overall vitality. Cellav operates a B2B model, partnering with global beauty brands like Miss Universe Skincare and medical-aesthetic clinics to bring science-driven regenerative treatments to the consumer market. With manufacturing supported by Pluri's GMP-certified facilities, Cellav aims to redefine the future of skin and hair health through scalable, high-quality biotechnological innovation.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Cellav.